Fig. 8: Comparison of DLBCL cutaneous lesions before and after treatment with Chidamide plus Rituximab. | Cell Death & Disease

Fig. 8: Comparison of DLBCL cutaneous lesions before and after treatment with Chidamide plus Rituximab.

From: Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Fig. 8

a–c Visual results, taken by camera. d, e CT images. f, g PET-CT images. a, d, f Images of patient with multiple cutaneous lesions before the treatment with Chidamide plus Rituximab. The arrows in ‘F’ indicate high-density masses under the skin and in the muscles.

Back to article page